Princess Alexandra Hospital, Brisbane

BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants

Retrieved on: 
Thursday, August 4, 2022
Medtech, University, BioCity Nottingham, Polycaprolactone, ISO, Senior lecturer, Quality of life, HBI, Pectus excavatum, BMBF, Patient, Company, Pain, Safety, Tissue, Hospital, Regional development, PCL, University of Queensland, SAB, Government, Education, Committee on European Affairs and Oversight of the European Funds, Solution, Health, Certification, Princess Alexandra Hospital, CMO, Princess Alexandra Hospital, Brisbane, Environment, CBCI, Medical device, Medical imaging, Royal Brisbane and Women's Hospital, Research

BellaSeno already published first-in-human data in 2021, demonstrating that its implant was able to camouflage a pectus excavatum defect not reconstructable by conventional techniques.

Key Points: 
  • BellaSeno already published first-in-human data in 2021, demonstrating that its implant was able to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
  • The second trial aims to enroll 20 patients who either need breast implant revision or surgery to correct congenital breast defects.
  • In both trials, patients will receive porous polycaprolactone implants produced in Bellasenos AI-driven additive manufacturing facilities by a no-touch approach.
  • The Company is developing novel resorbable soft tissue and bone reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification.

The Clinician joins AWS ISV Accelerate Program

Retrieved on: 
Tuesday, December 21, 2021
Amazon, Amazon Web Services, Lung cancer, Communication, Artificial intelligence, AWS, Princess Alexandra Hospital, Efficiency, SMS, ISV, Prom, PAH, Program, MENA, Princess Alexandra Hospital, Brisbane, Health, Patient, Medical imaging, Medicine, Clinician

The AWS ISV Accelerate Program is a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS.

Key Points: 
  • The AWS ISV Accelerate Program is a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS.
  • The AWS ISV Accelerate Program will provide The Clinician with co-sell support and benefits to connect with AWS field sellers globally, who service millions of active AWS customers.
  • "Having established a close relationship with AWS from the start of The Clinician's journey, we are thrilled to have been accepted into the AWS ISV Accelerate Program.
  • While developing ZEDOC, The Clinician joined the AWS Partner Network on the AWS Independent Software Vendor (ISV) Partner Path.

BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella

Retrieved on: 
Tuesday, December 7, 2021
Environment, Risk, Company, Pectus excavatum, Queensland University of Technology, BMBF, CMO, Plastic surgery, BioCity Nottingham, University, Medtech, SAB, Patient, CEO, Committee on European Affairs and Oversight of the European Funds, Deformity, Princess Alexandra Hospital, Government, Education, Certification, Princess Alexandra Hospital, Brisbane, ISO, Senior lecturer, Polycaprolactone, Regional development, Doctor of Philosophy, European Journal, University of Queensland, Breast, PCL, Medical imaging

Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .

Key Points: 
  • Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .
  • The highly porous polycaprolactone implant was well tolerated by the patient and resulted in an excellent aesthetic outcome.
  • The case study describes the first-in-human trial of soft tissue engineering to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
  • Senella therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.